Guardant360 CDx Gains European Union Certification for Tumor

Guardant360 CDx received In Vitro Diagnostic Regulation certification for tumor mutation profiling in solid tumors and for companion diagnostic indications in NSCLC and breast cancer.

Related Keywords

Germany , Helmy Eltoukhy , Peter Fasching , Cancer Center , D Product Service , Breast Cancer Center , Gynecological Cancer Center , National Comprehensive Cancer Network , European Union , Guardant Health , Vitro Diagnostic Regulation , National Comprehensive Cancer , Comprehensive Cancer Center ,